Associating these studies with the fact that PROTAC DT2216 has a limited effect on other types of leukemia than BCL‐XL‐dependent T‐ALL, Zhou's group has invested in developing a series of new VHL‐based PROTACs, which use the same TLM as the DT2216 (navitoclax).103. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.